What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Jean-Luc Harousseau focuses on Multiple myeloma, Internal medicine, Surgery, Oncology and Transplantation.
His Multiple myeloma research is multidisciplinary, incorporating elements of Cancer research and Bone marrow, Pathology.
The study incorporates disciplines such as Gastroenterology and Dexamethasone in addition to Surgery.
His biological study spans a wide range of topics, including Corticosteroid and Thalidomide.
His Oncology research is multidisciplinary, incorporating perspectives in Disease Response and Immunology.
His research integrates issues of Randomized controlled trial and Radiation therapy in his study of Chemotherapy.
His most cited work include:
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (2415 citations)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
- International uniform response criteria for multiple myeloma (2049 citations)
What are the main themes of his work throughout his whole career to date?
Jean-Luc Harousseau spends much of his time researching Internal medicine, Multiple myeloma, Surgery, Oncology and Transplantation.
His research combines Gastroenterology and Internal medicine.
His biological study deals with issues like Dexamethasone, which deal with fields such as Corticosteroid.
His Surgery study frequently links to related topics such as Lymphoma.
Jean-Luc Harousseau has researched Oncology in several fields, including Clinical trial, Hematology, Immunology, Bone marrow and Maintenance therapy.
His Transplantation research includes themes of Salvage therapy, Stem cell and Cumulative incidence.
He most often published in these fields:
- Internal medicine (63.22%)
- Multiple myeloma (46.63%)
- Surgery (39.42%)
What were the highlights of his more recent work (between 2009-2021)?
- Internal medicine (63.22%)
- Multiple myeloma (46.63%)
- Surgery (39.42%)
In recent papers he was focusing on the following fields of study:
Jean-Luc Harousseau mainly investigates Internal medicine, Multiple myeloma, Surgery, Transplantation and Bortezomib.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Oncology.
Multiple myeloma is frequently linked to Phases of clinical research in his study.
His Surgery research is multidisciplinary, relying on both Dexamethasone and Urology.
The concepts of his Transplantation study are interwoven with issues in Incidence, Cumulative incidence, Chemotherapy, Stem cell and Transplantation Conditioning.
The Bortezomib study combines topics in areas such as Prospective cohort study, Autologous transplantation, Pharmacology and Melphalan.
Between 2009 and 2021, his most popular works were:
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma (795 citations)
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (712 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His main research concerns Multiple myeloma, Internal medicine, Surgery, Transplantation and Oncology.
His Multiple myeloma research focuses on Hazard ratio and how it connects with Survival rate.
His Internal medicine research incorporates themes from Gastroenterology and Cancer research.
His studies deal with areas such as Very Good Partial Response, Pediatrics, Dexamethasone and Urology as well as Surgery.
His Transplantation study combines topics from a wide range of disciplines, such as Regimen, Disease progression, Chemotherapy and Standard treatment.
The Oncology study combines topics in areas such as Hematopoietic stem cell transplantation, Disease, Clinical trial and Minimal residual disease, Minimal Residual Disease Negativity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
